Publication of insider information pursuant to Art. 17 MAR

Jena, Germany | Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of €1,198.2m after nine months of fiscal year 2020/21 (past year: €967.9m). This corresponds to a revenue development of +23.8% vs. the past year (after adjustment for currency effects¹: +27.6%). In the third quarter of FY 2020/21, revenue amounted to €430.8m (past year: €253.0m) – a growth rate of +70.3% (after adjustment for currency effects: +75.3%) against the previous year’s period which had been heavily impacted by the COVID-19 pandemic. Revenue benefitted from a rise in recurring revenues as well as a further recovery in demand for equipment.

Earnings before interest and taxes (EBIT)² amounted to €282.8mafter nine months of FY 2020/21 (past year: €111.9m). EBIT margin (EBIT / revenue) was 23.6% (past year 11.6%). In the third quarter of FY 2020/21, EBIT amounted to €120.1m (past year: €9.4m). EBIT margin was 27.9% (past year: 3.7%). EBIT benefitted from a favorable development of product mix with a high share of recurring revenue. In addition, the ongoing low level of sales and marketing expenses as a result of the COVID-19 pandemic contributed to EBIT compared to the past year.

Earnings per share (EPS)³ amounted to €2.04 (past year: €0.77) for nine months of FY 2020/21. In the third quarter, EPS amounted to €0.91 (past year: €0.06).

Full results for nine months 2020/21 will be published on August 6, 2021.

In light of the positive business development, the company is raising targets for the current fiscal year 2020/21: revenue is expected to exceed the previous forecast of approximately EUR 1.6 billion (past year: EUR 1,335.5 million). The EBIT margin is expected to significantly exceed the previous target of around 20% in fiscal year 2020/21 (prior year: 13.3%), bolstered to a great extent by the current low selling and marketing expenses.